Recombinant HCG Gains Share as Urinary-Derived Segment Faces Structural Pivot

The human chorionic gonadotropin (hCG) market is undergoing a structural shift. The urinary-derived segment controlled 66.98% of revenue in 2025, but recombinant products are projected to grow at a faster 8.01% CAGR. Rising infertility rates—affecting approximately one in seven couples worldwide—and expanding ART cycles are key drivers. Clinical guidelines increasingly endorse hCG for male hypogonadism and azoospermia, with recent trials showing a 95.2% biochemical response rate for hCG monotherapy.